ArticleInternational journal of molecular sciences2026
TGBWDriver: A Cancer Driver Gene Identification Method Based on GraphSAGE and Bidirectional Weighted Feature Aggregation.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Identifying cancer driver genes is fundamental for understanding tumor initiation and guiding therapeutic strategies. However, most existing methods assess gene importance from a global or static perspective, overlooking sample-specific functional differences in the same gene. To address this, we propose TGBWDriver, which integrates a two-layer GraphSAGE with bidirectional weighted feature aggregation to capture structural characteristics while distinguishing context-dependent gene functions. An exponential pairwise voting strategy prioritizes candidate driver genes, improving ranking stability and accuracy. Systematic experiments on BRCA, LUAD, and PRAD datasets show that TGBWDriver outperforms five existing methods in precision, recall, and F1-score. Ablation studies confirm the critical role of each component. Moreover, TGBWDriver demonstrates strong capability in identifying potential novel cancer driver genes, with predictions showing significant biological relevance in GO enrichment and KEGG pathway analyses. The method provides an effective computational framework for cancer driver gene identification. The source code and datasets are freely available at https://github.com/SCSMDyeah/TGBW [Accessed on 4 May 2026].
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.